Pluri Inc (PLUR)

Pluri Inc. is a biotechnology company focused on research, development, and manufacturing of cell-based products, cell therapeutics, and related technologies. Its pipeline includes placenta-derived cell therapy candidates aimed at inflammatory conditions, muscle injuries, and hematologic disorders, along with an immunotherapy platform. Key programs include PLX-PAD, which is being studied for indications such as acute muscle injury after hip fracture, acute respiratory distress syndrome related to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia, and PLX-R18, a placenta-derived cell therapy under development for hematopoietic complications and in Phase I testing for hematopoietic cell transplantation. The company also works on an allogeneic MAIT cell therapy platform, offers cell manufacturing services and cell-based coffee, and develops cultivated meat products. Its activities span regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. Pluri has a collaboration with Bar-Ilan University on cancer immunotherapy for solid tumors, and it is based in Haifa, Israel.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.